Acquired epidermolysis bullosa (EB) is a rare skin disease characterized by the formation of blisters on the skin and mucous membranes that occur in response to mechanical trauma or other damage. EB is caused by a violation of the mechanical properties of the dermal and epidermal layers, which leads to weakness of the connections between them. Unlike hereditary epidermolysis bullosa, which is associated with genetic mutations, the acquired variant can be associated with various systemic diseases, infections and environmental factors. EB can have a severe course, especially in older people or with concomitant diseases, which requires careful diagnosis and targeted treatment.
History of the disease and interesting historical facts
Acquired epidermolysis bullosa was first described in literature following the widespread use of dermatological research in the mid-20th century. The exact time of the onset of the pathology is difficult to determine, but references to vesicular skin diseases can be found in ancient medical texts. Interestingly, at the beginning of the 20th century, many dermatologists classified bullous epidermolysis as a group of exudative erythema, which made diagnosis and treatment difficult. Only as a result of numerous clinical observations and studies did it become possible to distinguish EB as a separate disease.
Thus, there is increasing interest in the diagnosis of this condition, which, in turn, contributes to a better understanding of its pathogenesis and etiology, including the influence of systemic diseases and external factors.
Epidemiology
Statistics on EB are limited worldwide, but its prevalence is reported to vary by region and population. According to the World Health Organization, the incidence of EB is approximately 1–10 cases per million population. It is important to note that the disease is more common in older people, especially those with underlying medical conditions such as diabetes or malignancies.
It should also be noted that incidence data may be insufficiently complete due to the peculiarities of clinical manifestations, which leads to an underestimation of the prevalence of the disease.
Genetic predisposition to this disease
Acquired epidermolysis bullosa usually does not have a clear genetic predisposition, unlike its hereditary counterpart. However, it is known that changes in the expression level or functionality of certain genes can contribute to the development of the disease. In some cases, EB is associated with mutations in genes responsible for the synthesis of structural skin proteins, such as collagens, which can lead to secondary changes in the skin structure.
It is important to consider that mutations that contribute to acquired epidermolysis bullosa may be caused by external factors such as viral infections or autoimmune processes. As a result, diagnosis requires a comprehensive approach, including genetic testing in some cases.
Risk factors for the development of this disease
The development of epidermolysis bullosa acquisita can be associated with several groups of risk factors, including:
- Physical factors: skin injuries, inflammatory processes, burns.
- Chemical factors: use of aggressive topical preparations that irritate the skin.
- Infectious factors: viral and bacterial infections that can cause systemic inflammatory reactions.
- Systemic diseases: diabetes mellitus, autoimmune disorders, cancer.
Creating a tolerant environment may be important in prevention, in particular careful skin care and avoidance of trauma, which may reduce the likelihood of developing EBS in predisposed patients.
Diagnosis of this disease
The diagnosis of acquired epidermolysis bullosa involves several stages, starting with a clinical examination, where characteristic symptoms are noted, and ending with laboratory tests. The main symptoms of EB are:
- Formation of blisters on the skin after minor mechanical damage.
- Pain and itching in the area of the blisters.
- Erosions after rupture of blisters, which can become infected over time.
Laboratory tests include skin biopsy for histological analysis and immunoprofiling, which allows the detection of specific markers. Radiological methods, such as skin ultrasound, can be used to analyze the skin structure in more detail. Differential diagnosis is especially important to exclude hereditary forms of epidermolysis bullosa and other skin diseases, such as bullous dermatitis.
Treatment
Treatment of acquired epidermolysis bullosa should be comprehensive and include several approaches.
- General treatment: Inclusion of vitamins such as vitamin C in therapy to improve skin regeneration processes.
- Pharmacological treatment: administration of antibacterial and anti-inflammatory drugs to prevent secondary infections.
- Surgical treatment: In some cases, surgery may be required to remove damaged areas of skin or correct scars.
- Other treatments include physical therapy to improve skin condition and reduce pain.
The course of treatment should be selected individually, taking into account the patient’s condition and the characteristics of the course of the disease.
List of medications used to treat this disease
Some of the common medications used in the treatment of PBE include:
- Antibacterial drugs: Mupirocin, Fluconazole.
- Anti-inflammatory drugs: Diclofenac, Ibuprofen.
- Immunosuppressants: Methotrexate, Azathioprine.
These drugs help control the inflammatory process and avoid infectious complications, which is extremely important for improving the patient’s quality of life.
Disease monitoring
Monitoring of the patient's condition with PBE includes regular examinations by a dermatologist and assessment of the skin condition. The prognosis depends on the timely initiation of treatment and adequate control of possible complications:
- In the absence of adequate treatment, secondary infections and significant disability may develop.
- Some patients may experience serious complications requiring additional surgery.
The final stage of observation allows us to evaluate the effectiveness of treatment and, if necessary, adjust the tactics.
Age-related features of the disease
Acquired epidermolysis bullosa may present differently in different age groups.
- In children, the disease may begin to manifest itself as a result of direct trauma and stress, probably caused by infections.
- In adults, PBE is more often observed in combination with systemic diseases or in people exposed to chronic harmful factors.
- In elderly patients, the disease manifests itself most severely due to the presence of concomitant pathologies and a decrease in the regenerative capacity of the skin.
Understanding the age-related characteristics of the disease allows us to develop effective treatment strategies and improve the quality of life of patients.
Questions and Answers
- What is epidermolysis bullosa acquisita? This is a rare skin disease that causes blisters to form on the skin in response to mechanical damage.
- What are the main symptoms of PBE? The main symptoms include the formation of blisters, pain and itching at the site of the lesion, as well as possible infection of the erosions.
- How is PBE diagnosed? Diagnosis includes clinical examination, laboratory and radiological studies, as well as differential diagnosis with other skin diseases.
- What treatments are used for PBE? Treatment includes general therapy, the use of pharmacological agents, surgical interventions and physiotherapy.
- What is the prognosis for patients with PBE? The prognosis varies depending on the patient's condition and the severity of the disease, but with early diagnosis and adequate treatment, most patients can achieve a good quality of life.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov encourages patients with acquired epidermolysis bullosa to consider important aspects in skin care:
— Avoid mechanical trauma to the skin if possible.
- Use moisturizers to prevent skin from drying out and getting damaged.
— Consult a dermatologist regularly to monitor your condition and adjust your therapy.
— If blisters appear, act quickly: treat them with antiseptics if necessary and try to prevent infection.
Timely intervention and careful attention to the condition of the skin can significantly improve the quality of life of patients with this disease.
